埃拉贝拉:一种在心血管疾病中具有治疗潜力的多
Ping Yan1, Cuicui Meng2, Shujun Yang2
1Department of General Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Frontiers in cardiovascular medicine
|September 17, 2025
概括
埃拉贝拉 (ELA) 是一种小分子聚,对心血管健康至关重要. 本综述探讨了ELA的情况.
科学领域:
- 心血管科学 心血管科学
- 分子生物学分子生物学
- 医学研究 医学研究
背景情况:
- 心血管疾病 (CVD) 是一个重大的公共卫生挑战.
- 目前对心血管疾病的诊断和治疗策略需要改进.
- 小分子聚ELABELA (ELA) 已成为心血管健康的关键参与者.
研究的目的:
- 审查ELABELA (ELA) 在心血管发育中的作用及其潜在机制.
- 评估ELA在各种心血管疾病中的诊断价值和治疗潜力.
- 为了探索ELA在诸如子宫前,高血压和缺血-再输液损伤等疾病中的实用性.
主要方法:
- 关于研究ELABELA在心血管环境中的功能的文献综述.
- 分析ELA对心血管发育和疾病病理学的影响.
- 检查ELA的诊断标记和治疗应用.
主要成果:
- 埃拉贝拉 (ELA) 在心血管发育中发挥了重要作用.
- 埃拉具有作为心血管疾病诊断标记物的潜力.
- 在减少氧化应激,亡,纤维化和高血压方面,ELA已经显示出有效性,同时促进血管生成.
结论:
- 埃拉贝拉 (ELA) 是对心血管疾病的诊断和治疗的有希望的目标.
- 对针对ELA的药物的进一步研究可能会导致新的治疗策略.
- 本综述概述了基于ELA的诊断方法和心血管疾病的治疗方法.
更多相关视频
05:15Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
Published on: July 27, 2022
2.1K
07:35Non-chromatographic Purification of Recombinant Elastin-like Polypeptides and their Fusions with Peptides and Proteins from Escherichia coli
Published on: June 9, 2014
22.4K
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
